Medication info

Twinbeta Tablets 40/5/10 mg (Telmisartan, Amlodipine, Rosuvastatin)

Prescription medicationApproval withdrawn
Ingredient · strength
Telmisartan›Strength being verifiedAmlodipine Besylate›Strength being verifiedRosuvastatin Calcium›Strength being verified
Manufacturer / importer
Daewoong Bio Co., Ltd.
Appearance
Pink oval film-coated tablets
Packaging
30 tablets (10 tablets x 3)/PTP
Approval status
Approval withdrawn

MFDS item code 201803888 · Approved 2018.10.02

This product's status changed to Approval withdrawn on 2023.04.25. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension and dyslipidemia; inhibition of atherosclerosis progression and cardiovascular disease risk
Who uses it
Adults
Adult dosage
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking telmisartan/amlodipine combination therapy together with rosuvastatin as a single-agent product, they may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before initiating treatment with the telmisartan/amlodipine combination, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be started at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue this diet throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 mg once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response, and may be increased up to a maximum of 20 mg once daily. 2. Elderly patients: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended starting dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended starting dose for patients predisposed to myopathy is 5 mg. Administration of rosuvastatin 40 mg is contraindicated in some of these patients. In a drug interaction study of the active ingredients in this medicine, telmisartan/amlodipine 80/10 mg and rosuvastatin 20 mg, rosuvastatin Cmax increased approximately 2.4-fold and AUC approximately 1.3-fold in the presence of telmisartan/amlodipine. Therefore, when administering this medicine, assess the potential risk due to the increase in rosuvastatin Cmax and monitor patients closely.

Ingredients

Manufacturer
Daewoong Bio Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia; inhibition of atherosclerosis progression and cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary heart disease.
View approved original text

This drug is used for patients who need to take both Telmisartan/Amlodipine combination and Rosuvastatin simultaneously. The Telmisartan/Amlodipine combination helps effectively lower blood pressure in patients with essential hypertension, where blood pressure control is difficult with monotherapy. Rosuvastatin Calcium helps control cholesterol levels in patients with hypercholesterolemia and dyslipidemia, slowing the progression of atherosclerosis and reducing the risk of cardiovascular disease. It is particularly used to reduce the risk of stroke, myocardial infarction, and recurrence after vascular interventions in high-risk patients with elevated high-sensitivity C-reactive protein levels. The co-administration of these two drugs is effective in improving cardiovascular health by managing both blood pressure and cholesterol levels simultaneously. Therefore, this drug is used to prevent and improve cardiovascular diseases through blood pressure and lipid management.

Dosage and Administration

Adult dosage

Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking telmisartan/amlodipine combination therapy together with rosuvastatin as a single-agent product, they may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before initiating treatment with the telmisartan/amlodipine combination, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be started at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue this diet throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 mg once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response, and may be increased up to a maximum of 20 mg once daily. 2. Elderly patients: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended starting dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended starting dose for patients predisposed to myopathy is 5 mg. Administration of rosuvastatin 40 mg is contraindicated in some of these patients. In a drug interaction study of the active ingredients in this medicine, telmisartan/amlodipine 80/10 mg and rosuvastatin 20 mg, rosuvastatin Cmax increased approximately 2.4-fold and AUC approximately 1.3-fold in the presence of telmisartan/amlodipine. Therefore, when administering this medicine, assess the potential risk due to the increase in rosuvastatin Cmax and monitor patients closely.

Precautions

This drug can cause serious harm to the fetus and newborn during pregnancy, so it should be discontinued immediately if pregnancy is confirmed. Patients who are allergic to this drug's components or similar drugs, those with a history of angioedema, severely impaired liver or kidney function, or certain heart diseases should not take this medication. Elderly patients, patients with impaired liver function, significantly low blood pressure, and high serum potassium levels should use this drug with more caution, and regular blood tests and condition monitoring are necessary. This drug may cause muscle-related side effects, such as myalgia, muscle weakness, and rhabdomyolysis, so if muscle pain or weakness occurs during treatment, consult a doctor immediately. The Telmisartan component may affect kidney function, so patients with impaired kidney function need regular blood tests and monitoring. The Amlodipine component has blood pressure-lowering effects; thus, caution is needed in patients with excessively low blood pressure or poor cardiac function. The Rosuvastatin component can affect liver function, so regular liver enzyme tests should be done before and during treatment, and treatment should be discontinued if liver function abnormalities are found. This drug may interact with other medications; therefore, if other medications are being taken, patients must inform their doctor or pharmacist, especially when taking blood pressure medications, diuretics, anticoagulants, or immunosuppressants. Breastfeeding is not recommended while taking this drug; if it is necessary to take it, breastfeeding should be discontinued. Overdose may lead to hypotension, dizziness, and muscle abnormalities, so it is important to follow the dosage exactly and visit a healthcare facility immediately if abnormal symptoms occur. The safety and effectiveness of this drug in children have not been established, so it is recommended not to administer it to them. During treatment, drowsiness or dizziness may occur, so caution is advised when driving or operating dangerous machinery.

Side effects

  • Viral upper respiratory tract infection
  • dyspnea
  • hemorrhoidal bleeding
  • dyspepsia
  • atopic dermatitis
  • peripheral edema
  • peripheral edema
  • dizziness
  • orthostatic hypotension
  • low back pain
Show 195 more
  • headache
  • hepatocellular carcinoma
  • cerebral infarction
  • congestive heart failure
  • musculoskeletal pain
  • neck pain
  • nasopharyngitis
  • upper abdominal discomfort
  • upper abdominal pain
  • positional vertigo
  • dysuria
  • rhinitis
  • discomfort in the oropharynx
  • lung disease
  • unspecified intestinal disease
  • benign gastrointestinal neoplasm
  • hemorrhoids
  • skeletal pain
  • osteoporosis
  • sensory impairment
  • movement disorders
  • atherosclerosis
  • frequent urination
  • tinnitus
  • hearing loss
  • bad breath
  • fatty liver
  • headache
  • dizziness
  • low back pain
  • sinusitis
  • diarrhea
  • pharyngitis
  • influenza-like symptoms
  • dyspepsia
  • myalgia
  • urinary tract infection
  • abdominal pain
  • headache
  • dizziness
  • pain
  • fatigue
  • cough
  • hypertension
  • chest pain
  • nausea
  • peripheral edema
  • erectile dysfunction
  • increased sweating
  • flushing
  • allergies
  • fever
  • leg pain
  • malaise
  • palpitations
  • dependent edema
  • angina pectoris
  • rapid pulse
  • leg edema
  • abnormal ECG
  • insomnia
  • drowsiness
  • migraine
  • vertigo
  • sensory abnormalities
  • involuntary muscle contractions
  • sensory impairment
  • flatulence
  • constipation
  • gastritis
  • vomiting
  • dry mouth
  • hemorrhoids
  • gastroenteritis
  • enteritis
  • gastroesophageal reflux
  • toothache
  • nonspecific gastrointestinal disease
  • gout
  • hypercholesterolemia
  • diabetes
  • arthritis
  • arthralgia
  • leg numbness
  • anxiety
  • depression
  • irritability
  • infection
  • fungal infection
  • abscess
  • otitis media
  • asthma
  • bronchitis
  • rhinitis
  • epistaxis
  • dermatitis
  • rash
  • eczema
  • pruritus
  • vascular edema
  • frequent urination
  • cystitis
  • cerebrovascular disease
  • visual disturbances
  • conjunctivitis
  • ear pain
  • weakness
  • edema
  • vascular edema
  • palpitations
  • dizziness
  • flushing
  • headache
  • fatigue
  • nausea
  • abdominal pain
  • drowsiness
  • arrhythmia
  • bradycardia
  • chest pain
  • peripheral ischemia
  • syncope
  • orthostatic hypotension
  • vasculitis
  • peripheral neuropathy
  • tremors
  • loss of appetite
  • dysphagia
  • pancreatitis
  • gingival hyperplasia
  • allergic reaction
  • burning sensation
  • malaise
  • rigidity
  • weight gain
  • weight loss
  • osteoarthritis
  • muscle cramps
  • sexual dysfunction
  • insomnia
  • abnormal dreams
  • depersonalization
  • eosinophilia
  • thrombocytopenia
  • leucopenia
  • purpura
  • thrombocytopenia
  • heart failure
  • irregular pulse
  • skin depigmentation
  • dry skin
  • hair loss
  • dermatitis
  • muscle weakness
  • single contraction
  • coordination impairment
  • hypertonia
  • cold damp skin
  • apathy
  • anxiety
  • memory loss
  • gastritis
  • increased appetite
  • loose stools
  • rhinitis
  • urinary disorders
  • polyuria
  • abnormal olfaction
  • altered taste
  • abnormal eye movement control
  • xerophthalmia
  • gynecomastia
  • jaundice
  • elevated liver enzyme levels
  • leucopenia
  • confusion
  • exfoliative dermatitis
  • Stevens-Johnson syndrome
  • photosensitivity reaction
  • toxic epidermal necrolysis
  • vascular edema
  • diabetes
  • headache
  • dizziness
  • constipation
  • nausea
  • abdominal pain
  • pancreatitis
  • pruritus
  • rash
  • urticaria
  • myalgia
  • myopathy
  • rhabdomyolysis
  • weakness

Not everyone experiences these, and they can vary from person to person.

Storage

This drug is sensitive to light, so it should be stored in a container that blocks light. Additionally, it is important to store it at a temperature between 1 degree and 30 degrees Celsius to maintain its efficacy.

Appearance and packaging

Appearance

Pink oval film-coated tablets

Package unit

30 tablets (10 tablets x 3)/PTP

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.